Technology Development Recent Happenings

Inventors Recognition Program

In the second half of FY 2016, and the first half of FY 2017, NIAID recognized the following individuals for their contributions to the first U.S. patents issued in a patent family.

United States patent 9,353,353 was issued on May 31, 2016 for Virus-like particles (VLPs) prepared from chikungunya virus structural proteins. NIAID inventors: Srinivas Rao, D.V.M., Ph.D., M.B.A.

United States patent 9,365,626 was issued on June 14, 2016 for Simukunin. NIAID inventor: Ivo Francischetti, M.D., Ph.D. (no longer at NIH)

United States patent 9,375,424 was issued on June 28, 2016 for Compounds that treat malaria and prevent malaria transmission. NIAID inventors: Xinzhuan Su, Ph.D.

United States patent 9,441,019 was issued on September 13, 2016 for Influenza hemagglutinin protein-based vaccines NIAID inventor: Peter Kwong, Ph.D.

United States patent 9,453,239 Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes was issued on September 27, 2016 for NIAID Inventors: Bernard Moss, M.D., Ph.D., Linda Wyatt, Ph.D.

United States patent 9,475,862 was issued on October 25, 2016, for Neutralizing GP41 antibodies and their use. NIAID inventors: Mark Connors, M.D., Peter Kwong, Ph.D., John R. Mascola, M.D., Baoshan Zhang, Rebecca S. Rudicell, Yongping Yang, Ph.D.

United States patent 9,481,866 was issued on November 1, 2016, for Methods of producing T-cell populations enriched for stable regulatory T cells NIAID inventor: Ethan Shevach, M.D.

United States patent 9,487,563 was issued on November 8, 2016, for Virus-like particles and methods of use. NIAID inventors: Srinivas Rao, D.V.M., Ph.D., M.B.A.

United States patent 9,526,777 was issued on December 27, 2016, for Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein. NIAID inventors: Nancy J.Sullivan, Ph.D., Cheng Cheng

United States patent 9,534,041 was issued on January 3, 2017, for Monoclonal antibodies that neutralize a norovirus. NIAID inventors: Zhaochun Chen, Ph.D., Lisbeth Kim Green, Ph.D., Stanislav Sosnovtsev, Ph.D., Karin Bok, CRNP

United States patent 9,555,064 was issued on January 31, 2017, for Protease-deficient Bacillus anthracis. NIAID inventors: Andrei Pomerantsev, Ph.D., Stephen H. Leppla, Ph.D.

United States patent 9,624,475 was issued on April 18, 2017, for Genetically stable live attenuated respiratory syncytial virus vaccine and its production. NIAID inventors: Peter L. Collins, Ph.D.,Cindy L. Luongo, Ph.D., Ursula Buchholz, D.V.M., Ph.D.

Recent Patents

United States Patent 9,771,428 was issued on September 26, 2017 for CD47 targeted therapies for the treatment of infectious disease .  NIAID inventors: Kim Hasenkrug, Ph.D.

United States Patent 9,775,895 was issued on October 3, 2017 for HIV therapeutics and methods of making and using same.  NIAID inventor: Paolo Lusso, Ph.D.,

United States Patent  9,783,596  was issued on October 10, 2017, for Humanized monoclonal antibodies that specifically bind and/or neutralize Japanese encephalitis virus (JEV) and their use.  NIAID inventors: Robert Purcell, M.D.,

United States Patent 9,795,662 was issued on October 24, 2017 for Vaccine comprising AMA1 and RON2.   NIAID inventors: Prakash Srinivasan, Ph.D., Louis Miller, Ph.D.

United States Patent 9,624,475 was issued on April 18, 2017 for Genetically stable live attenuated respiratory syncytial virus vaccine and its production .  NIAID Inventors:  Peter L. Collins, Ph.D., Cindy L. Luongo, Ph.D.,  Ursula J Buchholz, DVM, Ph.D.

United States Patent 9,683,269 was issued on June 20, 2017 for Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof. NIAID Inventors: Robert Purcell, M.D.

United States Patent 9,738,703 was issued on August 22, 2017 for Neutralizing antibodies to HIV-1 and their use. NIAID Inventors: John Mascola, M.D., Mario Roederer, Ph.D., Peter Kwong, Ph.D.

United States Patent 9,730,993 was issued on August 15, 2017 for Engineered anthrax lethal toxin for targeted delivery. NIAID Inventors: Stephen H. Leppla, Ph.D.

United States Patent 9,738,689 was issued on August 22, 2017 for Prefusion RSV F proteins and their use. NIAID Inventors: Peter Kwong, Ph.D., Barney Graham, M.D., Ph.D., Michael Joyce, Ph.D. Tongqing Zhou, Ph.D.

United States Patent 9,707,287 was issued on July 18, 2017 for Attenuated mutant dengue viruses comprising a mutation in the NS4B non-structural protein. NIAID Inventors: Stephen S. Whitehead, Ph.D., Joseph E. Blaney, Ph.D., M.B.A.

United States Patent 9,708,392 was issued on July 18, 2017 for Monoclonal antibodies against orthopoxviruses. NIAID Inventors: Zhaochun Chen, Ph.D., Patricia Earl, Ph.D., Bernard Moss, M.D., Ph.D., Robert Purcell, M.D.

Recent Collaborative Agreements

NIAID and Amgen Inc. signed a material study of the CD300 family of receptors in collaboration with Bristol-Myers Squibb Company, for understanding their involvement in cancer and other inflammatory diseases to study the relative significance of IL17-RA and the adaptor protein CIKS in signaling by members of the IL-17 family of cytokines. NIAID principle investigator: Ulrich K. Siebenlist.

NIAID and MERCK SHARP & DOHME CORP. signed a human research collaboration agreement (RCA) to develop non-human primate challenge studies by Merck through its contractor and adds materials from NIAID. NIAID principle investigator: Richard A. Koup

NIAID and MERCK SHARP & DOHME CORP. signed a research collaboration agreement (RCA) to generate and test novel multi-specific antibodies for treatment of HIV-1 infection. NIAID principle investigator: Richard A. Koup

NIAID and the Broad Institute of MIT signed a research collaboration agreement (RCA) to utilize antisense oligonucleotides (ASOs) to silence the gene for human prion protein. NIAID principle investigator: Byron W. Caughey

NIAID and MaxCyte Inc. signed a research collaboration agreement (RCA) to develop a cell engineering process for ex vivo gene correction in autologous CD34+ hematopoietic stem cells for treatment of hereditary diseases. NIAID principle investigator: Harry L. Malech

NIAID and CureVac AG signed a cooperative research and development agreement (CRADA) to collaborate on mRNA vaccines and therapeutics for Filoviruses. NIAID principle investigator: Nancy J. Sullivan

NIAID and University of Brescia, Italy signed a human research collaboration agreement (RCA) to send human samples (DNA, Blood) to NIAID for genotyping and follow-up studies related to mast cells and tryptase. NIAID principle investigator: Joshua D. Milner

NIAID and Health Partners Institute signed a human research collaboration agreement (RCA) to transfer human samples from patients with systemic capillary leak syndrome (SCLS) to Dr. Dudek. NIAID principle investigator: Kirk M. Druey

NIAID and the San Diego VA Medical Center signed a human research collaboration agreement (RCA) to send de-identified patient samples to.characterize the phenotype of patients with physically induced urticaria.NIAID principle investigator: Dean D. Metcalfe

NIAID and PATH Malaria Vaccine Initiative (MVI) signed a human research collaboration agreement (RCA) to test new high sensitivity RDT kits, and identify individuals harboring low density Plasmodium falciparum infections and their contribution to transmission. NIAID principle investigator: Patrick E. Duffy

NIAID, Vaccine Research Center, and King's College London (KCL) signed a research collaboration agreement (RCA) to collaborate and study the physical and genetic properties of immune cells in blood collected from a large cohort of twins.NIAID principle investigator: Mario Roederer

NIAID and Bristol-Myers Squibb Company are collaborating to study the CD300 family of receptors to understand their involvement in cancer and other inflammatory diseases. NIAID principle investigator: John E. Coligan

NIAID and The National Institute for Communicable Diseases (“NICD”), the Centre for the AIDS Programme of Research in South Africa (“CAPRISA”) and the Vaccine Research Center (VRC) signed a research collaboration agreement (RCA) to characterize longitudinal samples from HIV-1 positive subjects from the CAPRISA clinical studies. NIAID principle investigator: John R. Mascola

NIAID and the University of Washington signed a research collaboration agreement (RCA) to focus on understanding the structure-function aspects of viral pathogen associated molecular pattern (PAMP) RNA binding to RIG-I. NIAID principle investigator: Joseph Marcotrigiano

NIAID and Griffith University (GU), Gold Coast Campus signed a research collaboration agreement (RCA) to transfer NIAID’s TBV antigen Pfs25 to GU researchers to incorporate a multi-component malaria vaccine.to be tested in mice. NIAID principle investigator: Patrick E. Duffy

NIAID and Roche Innovation Center signed a research collaboration agreement (RCA) to assess histo-cytometry and tissue clearing methods. NIAID principle investigator: Ronald N Germain

NIAID and Oxford University signed a research collaboration agreement (RCA) to request chAd-Ox1 plasmids for use in CCHF research. NIAID principle investigator: Heinz U. Feldmann

NIAID and University of Melbourne, AU signed a research collaboration agreement (RCA) to study and develop improved vaccines against influenza and other viral diseases. NIAID principle investigator: Barney S Graham

NIAID and Leica Microsystems, Inc. signed a research collaboration agreement (RCA) to assess histo-cytometry and tissue clearing methods. NIAID principle investigator: Ronald N. Germain

NIAID, Juno Therapeutics, and Fred Hutchinson Cancer Research Center (FHCRC), signed a research collaboration agreement (RCA) to construct chimeric antibody receptor (“CAR”) T cells using antibody binding receptors to SIV, and using VRC07-523 antibody binding receptor(s) to HIV.NIAID principle investigator: John R. Mascola

Content last reviewed on November 15, 2017